Acknowledgements
HL
This trial was funded by the Deutsche Krebshilfe (No. 108556 and 111744) and the Swiss State Secretariat for Education, Research and Innovation (SERI). We thank all participating patients, their families, and their treating physicians for helping to gather new insights for the treatment of future HL patients. We thank all participating GHSG HD16 trial sites for their continuous support. We also thank the Data Monitoring Board, which includes Prof Walter Lehmacher (Chair; Cologne, Germany), Prof Anton Hagenbeek† (Utrecht, Netherlands), Prof Martin Hutchings (Copenhagen, Denmark), and Dr Guido Schwarzer (Freiburg, Germany), for their valuable input and support.